Tufts University School of Medicine
Dr. Camilli is also a professor of molecular biology and microbiology at Tufts University School of Medicine.
As a postdoctoral associate at Harvard Medical School, Andrew Camilli needed a research topic. Inspired by ongoing research in the lab, he was struck by an idea. Could he build a molecular tool to systematically identify the deadly virulence proteins that cholera bacteria express as the infection proceeds?
Years later, that brief brainstorming session yielded a breakthrough method for analyzing diverse bacterial pathogens. Today, Camilli is doing research to understand how two such pathogens—Vibrio cholerae, which causes cholera, and Streptococcus pneumoniae, which causes pneumonia and middle-ear infection—become so virulent. His primary goal is to identify and characterize the function and regulation of specific genes and proteins that V. cholerae and S. pneumoniae express during different stages of infection. Ultimately, he hopes this work will lead to more effective vaccines and treatments.
Building on these early ideas, Camilli has developed several tools to identify bacterial virulence factors and expressed genes in vivo—inside an infected host. One such invention is a genetic technique called recombination-based in vivo expression technology (RIVET), which identifies bacterial genes that only activate during infection. Using RIVET, Camilli's lab has shown that V. cholerae expresses a critical virulence factor—intensifying cholera symptoms—only after an adhesive organelle on the surface of the bacteria has mediated attachment to tissues in the small intestine.
Camilli also became the first researcher to use DNA microarray technology to study the gene expression of a pathogen—again, V. cholerae—derived from naturally infected humans. He and colleagues compared gene expression levels and degree of infectivity of cholera bacteria grown in the lab with bacteria taken from watery stool specimens of cholera patients. They found that cholera bacteria shed from patients have a distinct gene expression pattern and have become an order of magnitude more infectious. Subsequent findings indicate that this enhanced infectivity is in part mediated by regulation of bacterial chemotaxis. In a later study, Camilli and colleagues created and used a variation of RIVET to show that V. cholerae also turns on a set of genes prior to leaving the host that enhance survival in the environment. Thus, they have shown that this pathogen prepares for both transmission and dissemination prior to leaving the cholera patient.
In other work, Camilli and colleagues learned how a transcription factor dubbed VieA modulates expression of cholera toxin. They found that VieA has an independently functioning domain that hydrolyzes and thus lowers the concentration of a signaling molecule, cyclic diguanylate, which in turn activates V. cholerae virulence genes and simultaneously represses the bacteria's ability to form a biofilm for environmental survival. By engineering the bacteria to cause misregulation of cyclic diguanylate levels in the cytoplasm, they can greatly reduce V. cholerae's virulence.
Separately, Camilli and colleagues are analyzing the S. pneumoniae genes that allow this bacterium to stably colonize the nasopharynx and to infect the lungs, causing pneumonia. Recently he developed a new tool, called Tn-seq, to simultaneously measure the roles of all of the bacterium's genes in infection. Tn-seq combines saturating transposon mutagenesis with massively parallel DNA sequencing of the transposon insertion junctions. Using this tool, Camilli's lab has identified new functions for many hypothetical genes, as well as additional functions for many known genes. These and other findings are being applied toward the development of novel vaccines.